Optimizing Rheumatoid Arthritis Therapy: Using Objective Measures of Disease Activity to Guide Treatment
After more than 2 centuries of work, we now understand more about the cellular biology of rheumatoid arthritis, but the underlying cause of the disease remains elusive.
Closing Gaps in Health Plan Performance with Stakeholder Collaboration
Kathryn Fitch, RN, MEd, Thomas Weisman, MD,MBA, Tyler Engel, ASA, MAAA, Adam Turpcu, PhD, Helen Blumen, MD, MBA, Yamina Rajput, MS, Purav Dave, MS, MBA
Cardiovascular-Related Healthcare Resource Utilization and Costs in Patients with Hypertension Switching from Metoprolol to Nebivolol
According to the Eighth Joint National Committee, hypertension is a known risk factor for cardiovascular (CV) events, such as stroke, myocardial infarction, and heart failure. Hypertension is defined as persistent systolic/diastolic blood pressure of at least 140/90 mm Hg among patients aged 70 billion in 2010 to an estimated $200 billion in 2030. The goal of therapy in patients with hypertension is to decrease the risk for CV events (such as myocardial infarction or stroke) by reducing and controlling blood pressure.
Moving Beyond Measures into Outcomes in Hypertension Research
Diagnosis and Treatment of Bipolar Disorders in Adults: A Review of the Evidence on Pharmacologic Treatments
Bipolar disorder is a chronic, relapsing illness characterized by recurrent episodes of manic or depressive symptoms, with intervening periods that are relatively (but not fully) symptom-free.
Bipolar Disorders: Balancing Formulary Management and Clinical Outcomes for a Vulnerable Patient Population
Utilization of Parenteral Anticoagulants and Warfarin: Impact on the Risk of Venous Thromboembolism Recurrence in the Outpatient Setting
Jennifer Cai, MS, MPH, Winghan Jacqueline Kwong, PharmD, PhD, Ronald Preblick, PharmD, MPH, Qiaoyi Zhang, MD, PhD, James T. Kenney, RPh, MBA
Venous thromboembolism (VTE) encompasses deep-vein thrombosis (DVT) and pulmonary embolism (PE). VTE is a chronic disease that is associated with a high risk for recurrence, especially during the initial months of therapy.
Better Compliance with Clinical Guidelines for Venous Thromboembolism Can Improve Patient Outcomes, Reduce Costs
Charles Jia-Haur Hu, DO, Chihyi Lin, DO, Brien Rex Miller, DO, Hanh Nguyen, DO, Quang T. Nguyen, DO, FACP, FACE, FTOS
Type 2 diabetes mellitus is an ongoing medical problem that clinicians deal with on a daily basis. The necessity of treating diabetes adequately is essential because of the many comorbidities and complications associated with uncontrolled diabetes.
Addressing Adherence a Key Challenge in the Management of Patients with Type 2 Diabetes
Evaluation of Dabigatran for Appropriateness of Use and Bleeding Events in a Community Hospital Setting
Anastasia L Armbruster, PharmD, BCPS, Katie S Buehler, PharmD, BCPS, Sun H Min, PharmD, Margaret Riley, PharmD, Michael W Daly, PharmD, MSCI, BCPS
The development of innovative medications is largely a private enterprise that relies chiefly on the investment of pharmaceutical companies in research and development (R&D).
Accurate Prescribing Key to Safe Use of Anticoagulants in Patients with Nonvalvular Atrial Fibrillation
Marco daCosta DiBonaventura, PhD, Ronda Copher, PhD, Enrique Basurto, MSc, Claudio Faria, PharmD, MPH, Rose Lorenzo, BA
Cardiovascular Events and Safety Outcomes Associated with Azithromycin Therapy: A Meta-Analysis of Randomized Controlled Trials
Azithromycin has been used for many years for the treatment of patients with various types of bacterial infections, as well as for the secondary prevention of coronary events. There is a growing concern, however, that azithromycin may be associated with an increased cardiovascular (CV) risk and may lead to CV-related death in high-risk patients.
Cardiovascular Safety of Azithromycin Therapy: Revisiting the Evidence
Page 6 of 13
Results 51 - 60 of 124
Results 51 - 60 of 124